KAN-101 for Celiac Disease
(SynCeD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
Who Is on the Research Team?
Study Director
Principal Investigator
Anokion SA
Are You a Good Fit for This Trial?
This trial is for people with Celiac Disease who have been on a gluten-free diet for at least a year. They should have certain genetic markers (HLA-DQ2.5), a previous diagnosis confirmed by tests, and specific biopsy results showing intestinal damage.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 3 intravenous (IV) infusions of KAN-101 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- KAN-101
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Lead Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University